Scholarlink

Purpose of Review <p>Concurrent chemoradiotherapy (cCRT) remains the standard of care for limited-stage SCLC (LS-SCLC), while long-term survival remains suboptimal. This review aims to summarize recent advances in combining immunotherapy with cCRT in LS-SCLC and highlight future directions in this evolving treatment landscape.</p> Recent Findings <p>The ADRIATIC trial demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) with durvalumab consolidation post-concurrent chemoradiotherapy (cCRT). Other studies explore various immunotherapeutic agents and combination strategies, underscoring the potential of PD-1/PD-L1 blockade and other novel targets such as BTLA and TIGIT in the treatment of LS-SCLC. However, challenges remain in determining the appropriate timing of immunotherapy and the optimal radiotherapy fraction schedule, as well as the role of prophylactic cranial irradiation (PCI) in the context of immunotherapy.</p> Summary <p>Integrating immunotherapy into LS-SCLC treatment represents a promising strategy with the potential to improve outcomes beyond what is achievable with cCRT alone. Ongoing trials are expected to provide further insights, potentially reshaping LS-SCLC treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in Immunotherapy and Chemoradiotherapy Combination for Limited-Stage Small-Cell Lung Cancer: Current Landscape and Future Frontiers

  • 期刊论文

  • 发表日期：

    2025年12月23日

查看全文
  • Jingze Zhang,
  • Xiao Zhong,
  • Shijiang Wang,
  • Linlin Wang

摘要

Purpose of Review

Concurrent chemoradiotherapy (cCRT) remains the standard of care for limited-stage SCLC (LS-SCLC), while long-term survival remains suboptimal. This review aims to summarize recent advances in combining immunotherapy with cCRT in LS-SCLC and highlight future directions in this evolving treatment landscape.

Recent Findings

The ADRIATIC trial demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) with durvalumab consolidation post-concurrent chemoradiotherapy (cCRT). Other studies explore various immunotherapeutic agents and combination strategies, underscoring the potential of PD-1/PD-L1 blockade and other novel targets such as BTLA and TIGIT in the treatment of LS-SCLC. However, challenges remain in determining the appropriate timing of immunotherapy and the optimal radiotherapy fraction schedule, as well as the role of prophylactic cranial irradiation (PCI) in the context of immunotherapy.

Summary

Integrating immunotherapy into LS-SCLC treatment represents a promising strategy with the potential to improve outcomes beyond what is achievable with cCRT alone. Ongoing trials are expected to provide further insights, potentially reshaping LS-SCLC treatment strategies.